

Stanford Cancer Institute

# Cancer Cell Therapy

Version Date:  
11 Sep 2020


## Classical Hodgkins Lymphoma (cHL) >12-75 Years

Relapsed or Refractory CD30  
Positive Classical Hodgkin  
Lymphoma

**CCT5040**  
Phase II  
CD30,CAR-T in  
Adult & Pediatric  
Relapsed/  
Refractory CD30  
Positive Classical  
HodgkinLymphoma  
  
PI: Arai  
Sponsor: Pending

### KEY


 Pending

 Open for Enrollment


 Observational Study

 Optional Path

 [Link](#) Trial Posting

 Enrollment on Hold

 Extension Study

 Immunotherapy